RECRUITING

Metoclopramide in Upper Gastrointestinal Bleed

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed? Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

Official Title

Premedication With Metoclopramide in Upper Gastrointestinal Bleeds a Prospective Double Blinded Single Center Randomized Control Trial in a Small Community Hospital

Quick Facts

Study Start:2023-05-20
Study Completion:2024-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05746377

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 and above
  2. * Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside
  3. * Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena
  4. * Plan to undergo EGD within 24 hours since admission or since first symptoms
  5. * Calculated Glasgow-Blatchford score ≥ 2
  1. * Failure to obtain informed consent
  2. * Known allergy to metoclopramide
  3. * Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome
  4. * History of TD or dystonic reaction to metoclopramide
  5. * Pheochromocytoma, catecholamine-releasing paragangliomas
  6. * Parkinson's Disease
  7. * Epilepsy
  8. * Pregnancy or lactation
  9. * Previous gastrectomy

Contacts and Locations

Study Contact

Mudassar K Sandozi, DO
CONTACT
(815) 971-2544
msandozi@mhemail.org
Altaf Dawood, MD
CONTACT
(815) 971-2544
adawood@mhemail.org

Study Locations (Sites)

Javon Bea Hospital-Riverside - MercyHealth
Rockford, Illinois, 61114
United States

Collaborators and Investigators

Sponsor: Mercy Health System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-20
Study Completion Date2024-06

Study Record Updates

Study Start Date2023-05-20
Study Completion Date2024-06

Terms related to this study

Keywords Provided by Researchers

  • metoclopramide
  • prokinetic
  • Upper endoscopy
  • EGD
  • endoscopic gastroduodenoscopy
  • esophagogastroduodenoscopy

Additional Relevant MeSH Terms

  • Upper GI Bleeding
  • Bleeds Gastric
  • Bleed Ulcer
  • Hemorrhage Gastric
  • Hemorrhage; Ulcer